The period to present pieces for Bioibérica's 1st Journalism Awards on heparin has been extended
- Participants can present their articles and reports until 31 October.
- The jury is formed by four renowned professionals from communications, medicine and science
- The goal of the competition is to recognise the best journalistic publications about heparin and incentivise the work by professionals who report on health, economy and biotechnology in Spain
- Heparin is the most commonly used anticoagulant and antithrombotic medication in the world and it is calculated that heparin saves more than 100 million lives each year
Bioibérica has convened the 1st Journalism Awards on Heparin in order to recognise the best journalistic articles and reports about this drug active from all its perspectives (history, application in health and medicine, economic and industrial dimensions, production process, new research and applications…). These awards also seek to incentivise the work by journalists in health communication and information, the economy and biotechnology in Spain, in the year when this biomolecule celebrates the centenary of its discovery.
The journalistic articles and periods published or issued in the Spanish media in any field of coverage (written press, online media, radio or television) during the period between 1 March and 30 October 2016 can be presented for the award. The prizes are endowed with a total of 6,000 Euros which is divided in two categories: written and online press, and audiovisual media.
The jury is formed by Dr José María Moraleda, president of the Spanish Society of Hematology and Hemotherapy; Mrs Fátima Lois, director of communications for Carlos III National Centre for Cardiovascular Research (CNIC); Mrs Lucía Cecilia, director of communications forAsebio; and by Mr Juan Carlos Esteban, Delegate in Catalonia of the Biotechnology Communicators Association.
Heparin is a drug which was discovered in 1916 in Johns Hopkins University in Baltimore (United States). Its action mechanism has been extensively described: it accelerates the inhibition of the proteins of the blood coagulation system and, as a result, prevents the formation of blood clots. As such, it is indicated to prevent arterial, venous and pulmonary thromboembolisms, coronary accidents, peripheral arterial diseases and atherosclerosis, among others. Heparin has a solid scientific basis, is highly proven in efficacy and, in spite of being a hundred year-old medication, remains in generalised clinical use, while new applications are being studied for the future in diseases such as malaria, cystic fibrosis or cancer.
Bioibérica is a Spanish biotechnology company specialised in identifying and isolating high therapeutic value biomolecules, with application in any of the areas of life sciences: human health, animal health or vegetable health. One of every five doses of heparin which is administered in the world is developed and manufactured in Spain by Bioibérica.
Related News
A crucial initiative to prevent shortages of critical medicines in the European Union.
The 28th Symposium on Glycosaminoglycans, an internationally renowned scientific event focusing on glycosaminoglycans, will be sponsored by
- Bioiberica produces 20% of the world's Heparin API.
- Heparin saves around a hundred million lives every year.
- One out of every 5 doses of heparin administered in the world comes from Bioiberica.